Clinical Trials Logo

Filter by:
NCT ID: NCT02079805 Completed - Clinical trials for Essential Hypertension Complicated by Type 2 Diabetes Mellitus

A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R

Start date: March 2014
Phase: Phase 4
Study type: Interventional

Multicenter, randomized, open-label, parallel-group exploratory study to explore the effects of azilsartan (Azirva), compared with telmisartan, on insulin resistance in patients with essential hypertension complicated by type 2 diabetes mellitus

NCT ID: NCT02078609 Completed - Clinical trials for AML and High Risk MDS

A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Start date: March 20, 2014
Phase: Phase 1
Study type: Interventional

This study will assess the safety and preliminary efficacy of escalating doses of LGH447 monotherapy in AML and MDS and LGH447 in combination with midostaurin in AML.

NCT ID: NCT02078219 Completed - Clinical trials for Gout and Hyperuricemia

Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia

Start date: January 5, 2014
Phase: Phase 2
Study type: Interventional

This study is to examine the hypothesis that administration of RDEA3170 to Japanese patients with gout or asymptomatic hyperuricemia in doses of 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg once daily, respectively will result in greater reduction of sUA compared to placebo.

NCT ID: NCT02077790 Completed - Clinical trials for Evaluate the Agreement and Precision of Device SS-1000 and the Predicate Device the Pentacam in a Reproducibility and Repeatability Trial

To Investigate the Precision and Agreement of SS-1000 and Pentacam in a Repeatability and Reproducibility Trial

PASP
Start date: September 2013
Phase: N/A
Study type: Interventional

This study is to support the substantial equivalence of the SS-1000 to the predicate device Pentacam. Primary Objective -The primary objective of the trial is to evaluate the precision of the SS-1000 and Pentacam in measuring the anterior segment parameters in an eye, including Corneal Curvature, Corneal Thickness, Anterior Chamber Depth and Cornea Volume. Secondary Objectives - To investigate the repeatability (intra-instrument) of SS-1000 and Pentacam in measuring the anterior segment parameters in an eye - To investigate the reproducibility (inter-instrument) of SS-1000 and Pentacam in measuring the anterior segment parameters in an eye - To investigate the agreement between SS-1000 and Pentacam in measuring the anterior segment parameters in an eye Study design -The trial design is a prospective precision trial with the following factors: The trial will be conducted at one investigational site. The site will have three SS-1000 devices and three Pentacam devices available. Three certified operators (#1, #2 and #3) will be randomly assigned to one set of devices (one SS-1000 and one Pentacam), such that operator effect are confounded with instrument effect. All participants will have one visit and undergo the same set of assessments. Each assessment will consist of 2 consecutive readings (M1, M2).

NCT ID: NCT02077647 Completed - Clinical trials for Osteoarthritis, Knee

Focused Registry on the Conservative Treatment of Osteoarthritis of the Knee

Start date: March 2014
Phase:
Study type: Observational [Patient Registry]

The primary objective of this registry is to assess the functional outcome measured with the Knee Injury and Osteoarthritis Outcome Score (KOOS) for patients with medial unicompartmental osteoarthritis and osteonecrosis of the knee treated conservatively. The aim of the Focused Registry is to complete the data collection and enable a sound analysis for the Tomofix Small size study.

NCT ID: NCT02074345 Completed - Clinical trials for Prevention of Infections Caused by Haemophilus Influenzae Type b

Phase III Study of Intramuscular TAK-816 in Healthy Infants

Start date: March 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety of intramuscular TAK-816 in healthy Japanese infants.

NCT ID: NCT02073981 Completed - Parkinson Disease Clinical Trials

Observational Study for Non-motor Symptoms and Treatment in Parkinson's Disease Patients

J-FIRST
Start date: March 2014
Phase:
Study type: Observational

This study is implemented to identify factors having an impact on improvement or exacerbation of non-motor symptoms, to provide information contributing to development of medical care in this field and improvement of patients' QOL, and to clarify the association between the use of istradefylline and non-motor symptoms or QOL.

NCT ID: NCT02073565 Completed - Clinical trials for Coronary Arteriosclerosis

HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt

HARMONEE
Start date: February 2014
Phase: N/A
Study type: Interventional

This is a multi-center, single-blind, randomized, active-controlled, clinical trial in Percutaneous Coronary Intervention (PCI) subjects. Subjects will be randomized to receive the Combo stent as the investigational treatment arm or an Everolimus Eluting Stent (EES) as the active-control arm.

NCT ID: NCT02073461 Completed - Acne Vulgaris Clinical Trials

Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.

Start date: March 2014
Phase: Phase 2
Study type: Interventional

This study is to assess the efficacy and safety of two concentrations of CD1579 (2.5% and 5%) versus vehicle in the treatment of acne vulgaris in the Japanese patients.

NCT ID: NCT02073448 Completed - Acne Vulgaris Clinical Trials

Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.

Start date: March 2014
Phase: Phase 3
Study type: Interventional

This study is to demonstrate the superiority in efficacy of the GK530G (fixed combination of CD0271 0.1% and CD1579 2.5%) versus each of the monads (CD0271 0.1% and CD1579 2.5%) in the treatment of acne vulgaris for up to 12 weeks, in the Japanese patients.